Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | CA9 | Q16790 | 1/20 | 0.49 |
| ▸ | APEX1 | P27695 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | SCN1A | P35498 | 2/20 | 0.42 |
| ▸ | SCN2A | Q99250 | 2/20 | 0.42 |
| ▸ | SCN3A | Q9NY46 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | F2 | P00734 | 2/20 | 0.41 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.41 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.41 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.41 |
| ▸ | HTR6 | P50406 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4630545 | 0.98 | CA1 (0.47) | CA1CA2CA9APEX1EPHX2 | |
| SCHEMBL4629452 | 0.95 | CA1 (0.50) | CA1CA2CA9APEX1SCN1A | |
| SCHEMBL2703626 | 0.88 | CA1 (0.53) | CA1CA2CA9APEX1SCN1A | |
| SCHEMBL878485 | 0.84 | CA1 (0.61) | CA1CA2CA9APEX1SCN1A | |
| SCHEMBL7393267 | 0.83 | CA1 (0.49) | CA1CA2CA9APEX1SCN1A | |
| SCHEMBL7394073 | 0.82 | CA1 (0.47) | CA1CA2CA9APEX1SCN1A | |
| SCHEMBL7883638 | 0.82 | CA1 (0.47) | CA1CA2CA9APEX1SCN1A | |
| SCHEMBL27202562 | 0.82 | CYP3A4 (0.62) | CA1CA2CA9APEX1SCN1A | |
| Dodecane SCHEMBL7645849 | 0.80 | SCN1A (0.49) | CA1CA2CA9SCN1ASCN2A | |
| SCHEMBL11696089 | 0.79 | CA1 (0.41) | CA1CA2CA9SCN1ASCN2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2287161-B1 | Derivatives of 4-piperazin-1-yl-4-benzo[b]thiophene suitable for the treatment of CNS disorders | OTSUKA PHARMA CO LTD (JP) | 2012-05-09 | — | — | EP | disclosed |
| EP-1919907-B9 | HETEROCYCLIC COMPOUND | OTSUKA PHARMA CO LTD (JP) | 2012-01-18 | — | — | EP | disclosed |
| EP-1919907-B1 | HETEROCYCLIC COMPOUND | OTSUKA PHARMA CO LTD (JP) | 2011-02-23 | — | — | EP | disclosed |
| US-7799797-B2 | Arylsulfonyl naphthalene derivatives and uses thereof | ROCHE PALO ALTO LLC (US) | 2010-09-21 | — | — | US | disclosed |
| US-7799797-B2 | Arylsulfonyl naphthalene derivatives and uses thereof | ROCHE PALO ALTO LLC (US) | 2010-09-21 | — | — | US | disclosed |
| US-7592456-B2 | Arylsulfonylnaphthalene derivatives as 5HT2A antagonists | MERCK SHARP & DOHME LIMITED (GB) | 2009-09-22 | — | — | US | disclosed |
| US-7592456-B2 | Arylsulfonylnaphthalene derivatives as 5HT2A antagonists | MERCK SHARP & DOHME LIMITED (GB) | 2009-09-22 | — | — | US | disclosed |
| CN-101472885-A | Arylsulfonyl naphthalene derivatives and uses thereof | HOFFMANN LA ROCHE (CH) | 2009-07-01 | — | — | CN | disclosed |
| CN-101472885-A | Arylsulfonyl naphthalene derivatives and uses thereof | HOFFMANN LA ROCHE (CH) | 2009-07-01 | — | — | CN | disclosed |
| EP-2041079-A1 | ARYLSULFONYL NAPHTHALENE DERIVATIVES AND USES THEREOF | F. Hoffmann-Roche AG (CH) | 2009-04-01 | — | — | EP | disclosed |
| WO-2007147763-A1 | ARYLSULFONYL NAPHTHALENE DERIVATIVES AND USES THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2007-12-27 | — | — | WO | disclosed |
| US-20070293526-A1 | Arylsulfonyl naphthalene derivatives and uses thereof | ROCHE PALO ALTO LLC | 2007-12-20 | — | — | US | disclosed |
| US-20070293526-A1 | Arylsulfonyl naphthalene derivatives and uses thereof | ROCHE PALO ALTO LLC | 2007-12-20 | — | — | US | disclosed |
| US-20070281952-A1 | Arylsulfonylnaphthalene Derivatives As 5Ht2a Antagonists | MERCK SHARPE & DOHME LIMITED (GB) | 2007-12-06 | — | — | US | disclosed |
| US-20070281952-A1 | Arylsulfonylnaphthalene Derivatives As 5Ht2a Antagonists | MERCK SHARPE & DOHME LIMITED (GB) | 2007-12-06 | — | — | US | disclosed |
| CN-101068776-A | As 5HT2AArylsulfonyl naphthalene derivatives as antagonists | MERCH SHARP & DOHME LTD (GB) | 2007-11-07 | — | — | CN | disclosed |
| CN-101068776-A | As 5HT2AArylsulfonyl naphthalene derivatives as antagonists | MERCH SHARP & DOHME LTD (GB) | 2007-11-07 | — | — | CN | disclosed |
| EP-1824817-A1 | ARYLSULFONYLNAPHTHALENE DERIVATIVES AS 5HT2A ANTAGONISTS | MERCK SHARP & DOHME LTD. (GB) | 2007-08-29 | — | — | EP | disclosed |
| WO-2007026959-A2 | DERIVATIVES OF 4-PIPERAZIN-1-YL-4-BENZ0 [B] THIOPHENE SUITABLE FOR THE TREATMENT OF CNS DISORDERS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-03-08 | — | — | WO | disclosed |
| WO-2006059149-A1 | ARYLSULFONYLNAPHTHALENE DERIVATIVES AS 5HT2A ANTAGONISTS | MERCK SHARP & DOHME LIMITED (GB) | 2006-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070293526-A1 | Arylsulfonyl naphthalene derivatives and uses thereof | ARSA, AR, SULT2A1 | CA1 4461/4885CA2 4084/4885CA9 3011/4885 |
| US-20070281952-A1 | Arylsulfonylnaphthalene Derivatives As 5Ht2a Antagonists | HTR2A, HTR2C, HTR1A | CA1 4627/4885CA2 4619/4885CA9 4869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.